Aug 25, 2020 | News
CHICAGO, AUGUST 25, 2020 — The Clinical trials investigating 16 promising therapies for Alzheimer’s and dementia are taking off thanks to $24 million in new grant funding from the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates....
Feb 12, 2020 | News
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2020 – T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today...
Feb 11, 2020 | News
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 – T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today...
Nov 6, 2019 | News
T3D Therapeutics is now fully funded to initiate the Phase 2 PIONEER Study of T3D-959 in Mild-to-Moderate Alzheimer’s Disease Patients RESEARCH TRIANGLE PARK, N.C., Nov. 4, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the...
May 20, 2019 | News
Research Triangle Park, NC, May 20, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the “Company”), a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a grant...
